Nexavar granted FDA Priority Review for treatment of liver cancer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that the supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that the supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Nexavar is currently approved in more than 50 countries for the treatment of patients with advanced kidney cancer. Priority Review designation is intended to expedite the regulatory review process for investigational agents or uses that address unmet medical needs.
Based on this designation, the FDA reviews the application with a goal of taking action within six months of the date on which they received the sNDA. "This Priority Review underscores the potential of Nexavar to be a significant advance in the treatment of liver cancer," said Susan Kelley, vice president of Therapeutic Area Oncology at Bayer HealthCare Pharmaceuticals.
"If approved, Nexavar would be the first FDA-approved therapy for patients battling this devastating disease," she added.
The sNDA submission, completed in June 2007, was based on data from the Phase 3 SHARP trial which demonstrated that Nexavar extended overall survival by 44 percent in patients with HCC (HR=0.69; p=0.0006) versus placebo. There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups with the most commonly observed adverse events in patients receiving Nexavar being diarrhea and hand-foot skin reaction.
Based on this data, the companies also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) in June.
Hank Fuchs, executive vice president and chief medical officer of Onyx said: "Our comprehensive development program continues to identify new areas where Nexavar's unique combination of multi-targeted activity, tolerability and oral dosing may meet additional unmet needs in cancer."